Uncovering the roots of Parkinson's disease, together

A global basic research initiative

Aligning Science Across Parkinson’s (ASAP) is fostering collaboration and resources to better understand the underlying causes of Parkinson’s disease. With scale, transparency, and open access data sharing, we believe we can accelerate the pace of discovery, and inform the path to a cure.

Explore the New GP2 Section

The Global Parkinson’s Genetics Program (GP2) is an ASAP-funded five-year resource program to genotype >150,000 volunteers around the world to further understand the genetic architecture of Parkinson’s disease (PD). This year, ASAP launched new web pages dedicated to GP2's efforts. Learn more about GP2’s Working Groups, blog, professional opportunities, and accessing GP2’s new online learning platform.

Visit GP2

Meet ASAP’s 2020 Grantees

Meet the new members of ASAP’s Collaborative Research Network. Multidisciplinary investigators in 21 teams from 60 institutions across 11 countries, seek to accelerate targeted basic research and move us toward more meaningful advancements for Parkinson’s Disease. Get to know these talented scientists, their projects and how their outcomes will contribute to the field of PD.

Meet our CRN teams

GP2 Launches Training Platform

GP2’s new online learning platform makes development opportunities accessible and enables learners from around the world to explore courses on topics related to Parkinson’s disease genetics and a range of related areas. It is easy to register and available to everyone interested.

Visit GP2 Training

Latest News

2020: A Year in Review

This proved to be a formative year in the fight against Parkinson’s. Check out ASAP’s 2020 efforts and progress in better understanding the underlying causes of PD.

Learn More

Aligning Science Across Parkinson's Awards $161 Million in Grants

Philanthropy News Digest featured ASAP in this article detailing what our grantees hope to accomplish with their research.

Learn More

Developing Therapies for Parkinson’s

The Lancet highlights the work we do with our AMP-PD partners in enabling meaningful progress in the development of new therapies to treat Parkinson’s disease.

Learn More
See More News

Be a part of a global initiative to influence the culture of the way we do science.